20.500.12556/RUL-180305 Effect of biological therapy on symptom burden and functional disability in patients with migraine a before-and-after analysis Vpliv biološkega zdravljenja na simptomsko obremenitev in funkcionalno prizadetost pri bolnikih z migreno pre–post analiza Introduction This study aims to assess the effectiveness of biological therapies in reducing migraine-related symptom burden and functional disability, including reductions in monthly migraine days, pain intensity, and analgesic consumption, among patients with migraine in Slovenia. Methods This retrospective study analysed 92 adult patients with migraine receiving prophylactic biological treatment at the University Medical Centre Ljubljana. Average number of monthly migraine days (MMD), average analgesic consumption, pain intensity (VAS), and functional disability score (MIDAS) were collected before treatment and after 3 and 12 months. Statistical analysis involved the Friedman test to assess changes over time, followed by Wilcoxon tests with Bonferroni correction for post hoc comparisons. Results 83 patients completed 12 months of treatment. Significant reductions (p < 0.001) were observed in MMD (median 10 vs. 2 days), analgesic consumption, VAS scores (median 8 vs. 4), and MIDAS scores after 3 months (median 19 vs. 2), sustained at 12 months. Treatment discontinuation occurred in 9 patients due to inefficacy or side effects. Most patients tolerated biologics well, with mild adverse effects reported. Conclusions Biological therapies significantly reduced migraine-related symptom burden and functional disability, including decreases in migraine frequency, pain intensity, and analgesic use, in a Slovenian migraine cohort. These findings support the use of biologics as effective and safe options for migraine prevention in real-world clinical practice. Uvod Namen raziskave je bil oceniti učinkovitost biološkega zdravljenja pri zmanjševanju simptomske obremenitve in funkcionalne prizadetosti pri bolnikih z migreno v Sloveniji, vključno z zmanjšanjem mesečnega števila migrenskih dni, intenzivnosti bolečine in porabe analgetikov. Metode V retrospektivni študiji smo analizirali 92 odraslih bolnikov z diagnozo migrene, zdravljenih z biološkimi zdravili v Univerzitetnem kliničnem centru Ljubljana. Zbrali smo podatke o povprečnem številu migrenskih dni na mesec (MMD), povprečni porabi analgetikov, intenzivnosti bolečine (VAS) in funkcionalni onesposobljenosti (MIDAS) na treh časovnih točkah: pred začetkom zdravljenja, po 3 in 12 mesecih zdravljenja. Statistična analiza je vključevala Friedmanov test za oceno sprememb skozi čas, sledili pa so Wilcoxonovi testi z Bonferronijevo korekcijo za post hoc primerjave. Rezultati Skupno je 83 bolnikov zaključilo 12-mesečno zdravljenje. Po treh mesecih smo zaznali statistično značilno zmanjšanje MMD (mediana z 10 na 2 dni), porabe analgetikov, bolečine po VAS lestvici (mediana z 8 na 4) ter funkcionalne onesposobljenosti po MIDAS lestvici (mediana z 19 na 2), ki so se ohranile tudi po 12 mesecih (p < 0,001). Zdravljenje je v prvem letu prekinilo 9 bolnikov, bodisi zaradi neučinkovitosti ali neželenih stranskih učinkov. Večina bolnikov je biološka zdravila dobro prenašala, pri čemer so bili poročani neželeni učinki večinoma blagi. Zaključki Biološka terapija slovenski kohorti bolnikov z migreno pomembno zmanjšuje simptomsko obremenitev in funkcionalno prizadetost, vključno z zmanjšanjem pogostosti napadov, intenzivnosti bolečine in uporabe analgetikov. Ti rezultati podpirajo uporabo bioloških zdravil kot učinkovitih in varnih možnosti za preprečevanje migrene v klinični praksi. monoclonal antibodies neurology disability evaluation preventive treatment monoklonska protitelesa nevrologija ocenjevanje invalidnosti preventivno zdravljenje true false true Angleški jezik Slovenski jezik Članek v reviji 2026-03-05 14:14:04 2026-03-05 14:14:06 2026-03-06 04:33:09 0000-00-00 00:00:00 2026 0 0 Str. 34-40 no. 1 Vol. 65 2026 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2026-01-01 616.857 0351-0026 10.2478/sjph-2026-0005 270641411 Effect_of_Biological_Therapy_on_Symptom_Burden_and_Functional_Disability_in_Patients_with_Migraine_A.pdf Effect_of_Biological_Therapy_on_Symptom_Burden_and_Functional_Disability_in_Patients_with_Migraine_A.pdf 1 9AAF8168C2A76A139A05E45C93CAE07F 0da0bf38316cd9c81ecf2f2ae8dcb05d982a36fbeebd4e6fcf2967ac772ec148 b451d6e9-1895-11f1-a1ba-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=229545 https://reference-global.com/article/10.2478/sjph-2026-0005 1 d1e623a0-1894-11f1-a1ba-0050569b8976 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=229544 Zdravstvena fakulteta 0 0 0